NAMS
NewAmsterdam Pharma Company N.V.
$30.45
+$0.73(+2.46%)
50
Overall
50
Value
45
Tech
55
Quality
Market Cap
$3.96B
Volume
1.28M
52W Range
$15.82 - $42.00
Target Price
$49.92
Company Overview
| Mkt Cap | $3.96B | Price | $30.45 |
| Volume | 1.28M | Change | +2.46% |
| P/E Ratio | -19.4 | Open | $30.78 |
| Revenue | $22.5M | Prev Close | $29.72 |
| Net Income | $-203.8M | 52W Range | $15.82 - $42.00 |
| Div Yield | N/A | Target | $49.92 |
| Overall | 50 | Value | 50 |
| Quality | 55 | Technical | 45 |
No chart data available
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest News
NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
TipRanks Auto-Generated Newsdesk•3 days ago
NewAmsterdam Pharma Company (NAMS) Receives a Buy from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $30.45 | +2.5% | 1.28M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW